Novocure Reports First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.